risk, one obvious course of action is to maintain the status quo. This is currently the most prudent approach, especially in secondary prevention settings where the benefits of aspirin are indisputable and greatly exceed the risk. 8 For primary prevention of cardiovascular disease, where the evidence is less certain, 9 the decision to prescribe aspirin should be predicated on the balance of risks (bleeding and possibly AMD) and benefits (cardiovascular disease and possibly cancer). For guidelineeligible patients (the 10-year risk of myocardial infarction in men aged 45-79 years is Ͼ4%, and the 10-year risk of stroke in women aged 55-79 years is Ͼ3%, and in whom the bleeding risk is low), 10 the presence or absence of strong risk factors for neovascular AMD might tilt treatment decisions in one direction or the other. For patients taking long-term aspirin for other indications (pain control), caution is warranted in light of these observations. In the final analysis, decisions about aspirin use are best made by balancing the risks against the benefits in the context of each individual's medical history and value judgments. 
EDITOR'S NOTE
The Incremental Nature of Clinical Research T he eloquent Invited Commentary by Kaul and Diamond illustrates the great care that must be taken before concluding that an association described in an observational study truly represents a cause-effect relationship. In our discussion of the article by Liew and colleagues, the editors believed that it provided useful incremental data about an important condition. However, as with many good studies, the data are not definitive enough to suggest changes in clinical practice. Rather, we hope the study galvanizes more research on the relationship between aspirin and macular degeneration. For example, ASPREE (Aspirin in Reducing Events in the Elderly), a large international, randomized controlled trial on the effect of aspirin on cardiovascular outcomes and dementia in elderly persons, hopefully will consider rigorously assessing for macular degeneration.
After the editors decided to accept this article, we discussed the risk that press reports would fall into the trap of reporting this study as definitive. This study provides an opportunity to educate the public about the subtleties and incremental nature of medical research. Our understanding of disease etiology advances as evidence accumulates from multiple good studies.
